Skip to main content
. 2018 Nov 12;8:16668. doi: 10.1038/s41598-018-35072-5

Figure 3.

Figure 3

Kaplan-Meier survival analyses based on c-MYC copy number variation (CNV) before and after neoadjuvant chemotherapy. In the pre-neoadjuvant chemotherapy (NAC) samples, c-MYC amplification (A) and copy number gain (B) were not associated with disease-free survival of the patients, while a high Shannon index for c-MYC CNV (C) shows a significant association with poor disease-free survival. Similarly, in the post-NAC samples, c-MYC amplification (D) and copy number gain (E) were not associated with disease-free survival, and a high Shannon index (F) shows a significant association with poor disease-free survival.